- Home
- BST vs PHVS Comparison
BST vs PHVS Comparison
Compare BST & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BST
- PHVS
- Stock Information
- Founded
- BST 2014
- PHVS 2015
- Country
- BST United States
- PHVS Netherlands
- Employees
- BST N/A
- PHVS N/A
- Industry
- BST Finance Companies
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- BST Finance
- PHVS Health Care
- Exchange
- BST Nasdaq
- PHVS Nasdaq
- Market Cap
- BST 1.2B
- PHVS 1.0B
- IPO Year
- BST N/A
- PHVS 2021
- Fundamental
- Price
- BST $38.23
- PHVS $19.14
- Analyst Decision
- BST
- PHVS Strong Buy
- Analyst Count
- BST 0
- PHVS 5
- Target Price
- BST N/A
- PHVS $40.60
- AVG Volume (30 Days)
- BST 105.9K
- PHVS 46.7K
- Earning Date
- BST 01-01-0001
- PHVS 11-13-2024
- Dividend Yield
- BST 8.18%
- PHVS N/A
- EPS Growth
- BST N/A
- PHVS N/A
- EPS
- BST N/A
- PHVS N/A
- Revenue
- BST N/A
- PHVS N/A
- Revenue This Year
- BST N/A
- PHVS N/A
- Revenue Next Year
- BST N/A
- PHVS N/A
- P/E Ratio
- BST N/A
- PHVS N/A
- Revenue Growth
- BST N/A
- PHVS N/A
- 52 Week Low
- BST $29.62
- PHVS $15.21
- 52 Week High
- BST $37.96
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- BST 62.50
- PHVS 55.68
- Support Level
- BST $36.21
- PHVS $15.21
- Resistance Level
- BST $37.98
- PHVS $19.59
- Average True Range (ATR)
- BST 0.64
- PHVS 1.42
- MACD
- BST 0.09
- PHVS 0.14
- Stochastic Oscillator
- BST 59.62
- PHVS 93.82
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.